Less than 24 hours to go…
It’s the eve of the election, and a lot is at stake for investors. From tech regulation, to taxes and energy policy, there’s a ton riding on the outcome. We’ll follow everything you need to know – including the record money pouring into campaigns, and all the possible outcomes for stocks in the coming days. Plus, our own Meg Tirrell explains why Regeneron’s promising COVID-19 antibody treatment would be in short supply if the FDA approved it today.
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
It’s the eve of the election, and a lot is at stake for investors.
From tech regulation, to taxes and energy policy, there’s a ton riding on the outcome.
We’ll follow everything you need to know – including the record money pouring into campaigns, and all the possible outcomes for stocks in the coming days.
Plus, our own Meg Tirrell explains why Regeneron’s promising COVID-19 antibody treatment would be in short supply if the FDA approved it today.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.